Utah Doctor's Fentanyl Lies Lead to Permanent DEA Registration Revocation
Published Date: 1/15/2026
Notice
Summary
Dr. Mark Huff from Utah lost his DEA license because he wasn’t honest about his fentanyl abuse and treatment during a government investigation. The DEA decided his actions could harm public safety, so they ended his registration. This means Dr. Huff can no longer legally handle controlled substances, effective immediately, impacting his medical practice and patients.
Analyzed Economic Effects
3 provisions identified: 0 benefits, 3 costs, 0 mixed.
DEA Registration Revoked for Dr. Mark Huff
Dr. Mark Huff’s DEA Certificate of Registration No. FH6657716 is revoked, effective February 17, 2026. This means Dr. Huff can no longer legally handle controlled substances and the revocation applies immediately on that date.
Pending DEA Applications Denied
The Order also denies any pending applications of Mark Huff to renew or modify DEA registration and denies any other pending application for additional registration in Utah, effective February 17, 2026. Those pending requests will not be granted after that date.
Patients May Lose Access To Controlled Drugs
Patients of Dr. Mark Huff may no longer receive prescriptions or other legally authorized access to controlled substances from him after February 17, 2026. The Order explicitly notes the revocation impacts his medical practice and patients.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-13705 — Importer of Controlled Substances Application: Benuvia Operations, LLC.
Benuvia Operations, LLC wants to become an official importer of certain controlled substances like marijuana extract and psilocybin. People and companies involved with these drugs can share their thoughts or ask for a hearing by August 6, 2026. This move could shake up who gets to bring these substances into the U.S., so keep an eye on the deadline if you’re interested!
2026-13581 — Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I
Starting July 6, 2026, the DEA plans to temporarily put three substances related to 7-hydroxymitragynine—Mitragynine Pseudoindoxyl, MGM-15, and MGM-16—into Schedule I, the strictest drug category. This means anyone making, selling, or using these chemicals will face tough legal rules and penalties. The move aims to control these substances quickly while the DEA studies them further, affecting businesses and researchers handling these compounds.
2026-13580 — Schedules of Controlled Substance: Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I
Starting July 6, 2026, the DEA plans to temporarily put 7-hydroxymitragynine above a certain amount into Schedule I, meaning it’s treated like the most tightly controlled drugs. This affects anyone who makes, sells, studies, or even just has this substance, bringing strict rules and penalties. The move aims to keep people safe while the government figures out the long-term plan.
2026-13364 — Schedules of Controlled Substances: Temporary Placement of 5,6- Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the Controlled Substances Act
Starting July 1, 2026, the DEA is temporarily putting four new substances—5,6-dichloro brorphine, 5,6-dichloro desmethylchlorphine, N-propionitrile chlorphine, and spirochlorphine—into Schedule I, the strictest drug category. This means anyone making, selling, or using these chemicals will face tough legal rules and penalties. The move helps keep these potentially dangerous drugs off the streets while the DEA studies them further.
Previous / Next Documents
Previous: 2026-00613 — Notice of Request for Revision to and Extension of Approval of an Information Collection; Communicable Diseases in Horses
The USDA wants to update and keep collecting info about horses that test positive for a contagious disease called equine infectious anemia. This affects horse owners, vets, and labs that test horses moving between states. They’re asking for public comments by March 16, 2026, and the changes won’t cost anyone extra but will help keep horses healthy and safe.
Next: 2026-00622 — Proviso Railroad, Inc.-Acquisition Exemption-L. Neill Cartage Co., Inc.
Proviso Railroad, Inc. is set to take over and operate a short rail line owned by L. Neill Cartage Co. in Berkeley, Illinois, used for moving goods like paper and lumber. This change kicks in on January 29, 2026, with no big money shifts expected since Proviso’s revenue stays small. The move keeps future rail connections open and promises smooth cargo swaps with Union Pacific Railroad.